The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.